Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retigabine - Xenon Pharmaceuticals

Next Previous
Drug Profile

Retigabine - Xenon Pharmaceuticals

Alternative Names: Ezogabine - Xenon Pharmaceuticals; XEN-496

Latest Information Update: 05 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xenon Pharmaceuticals
  • Class Antiepileptic drugs; Carbamates; Fluorobenzenes; Phenylenediamines; Small molecules
  • Mechanism of Action GABA A receptor agonists; KCNQ potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Early infantile epileptic encephalopathy 2
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Early infantile epileptic encephalopathy 2

Most Recent Events

  • 18 Dec 2023 Xenon Pharmaceuticals terminates phase III clinical trials in Early infantile epileptic encephalopathy 2 (Adjunctive treatment, In children, In infants) in US, Australia, Belgium, Spain, France and Italy (PO) (NCT04912856) (EudraCT2020-003447-28)
  • 28 Jun 2023 Xenon Pharmaceuticals terminates phase III trial because of sponsor decision in Early-infantile epileptic encephalopathy-2 (Adjunctive treatment, In children, In infants) in Australia, Belgium, Spain, Italy and USA (NCT04639310)
  • 15 May 2023 Discontinued - Phase-III for Early infantile epileptic encephalopathy 2 (Adjunctive treatment, In children, In infants) in France (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top